Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 55

1.

AlloHSCT for inv(3)(q21;q26)/t(3;3)(q21;q26) AML: a report from the acute leukemia working party of the European society for blood and marrow transplantation.

Halaburda K, Labopin M, Houhou M, Niederwieser D, Finke J, Volin L, Maertens J, Cornelissen JJ, Milpied N, Stuhler G, Kröger N, Esteve J, Mohty M, Nagler A.

Bone Marrow Transplant. 2018 Jun;53(6):683-691. doi: 10.1038/s41409-018-0165-x. Epub 2018 Apr 18.

PMID:
29670208
2.

Cyclophosphamide versus etoposide in combination with total body irradiation as conditioning regimen for adult patients with Ph-negative acute lymphoblastic leukemia undergoing allogeneic stem cell transplant: On behalf of the ALWP of the European Society for Blood and Marrow Transplantation.

Czyz A, Labopin M, Giebel S, Socié G, Apperley J, Volin L, Reményi P, Yakoub-Agha I, Orchard K, Michallet M, Stuhler G, Chaganti S, Murray M, Aljurf M, Bloor A, Passweg J, Finke J, Mohty M, Nagler A.

Am J Hematol. 2018 Jun;93(6):778-785. doi: 10.1002/ajh.25091. Epub 2018 Mar 30.

PMID:
29574915
3.

Anti-CD20 immunotherapy as a bridge to tolerance, after allogeneic stem cell transplantation for patients with chronic lymphocytic leukaemia: results of the CLLX4 trial.

Schetelig J, Link CS, Stuhler G, Wagner EM, Hänel M, Kobbe G, Böttcher S, Kreuzer KA, Middeke JM, Sockel K, Teipel R, von Bonin M, Stölzel F, Kramer M, Stilgenbauer S, Hallek M, Bornhäuser M; Deutsche CLL Studiengruppe and the German Cooperative Transplant Study Group.

Br J Haematol. 2018 Mar 12. doi: 10.1111/bjh.15181. [Epub ahead of print] No abstract available.

PMID:
29528122
4.

Allogeneic stem cell transplantation in acute lymphoblastic leukemia patients older than 60 years: a survey from the acute leukemia working party of EBMT.

Roth-Guepin G, Canaani J, Ruggeri A, Labopin M, Finke J, Cornelissen JJ, Delage J, Stuhler G, Rovira M, Potter M, Stadler M, Veelken H, Cahn JY, Collin M, Beguin Y, Giebel S, Nagler A, Mohty M.

Oncotarget. 2017 Dec 4;8(68):112972-112979. doi: 10.18632/oncotarget.22934. eCollection 2017 Dec 22.

5.

What is the outcome in patients with acute leukaemia who survive severe acute graft-versus-host disease?

Ringdén O, Labopin M, Sadeghi B, Mailhol A, Beelen D, Fløisand Y, Ghavamzadeh A, Finke J, Ehninger G, Volin L, Socié G, Kröger N, Stuhler G, Ganser A, Schmid C, Giebel S, Mohty M, Nagler A.

J Intern Med. 2018 Feb;283(2):166-177. doi: 10.1111/joim.12695. Epub 2017 Nov 3.

PMID:
29027756
6.

Long-Term Follow-Up and Impact of Comorbidity before Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Relapsed or Refractory Acute Myeloid Leukemia-Lessons Learned from the Prospective BRIDGE Trial.

Middeke JM, Herbst R, Parmentier S, Bug G, Hänel M, Stuhler G, Schäfer-Eckart K, Rösler W, Klein S, Bethge W, Bitz U, Büttner B, Knoth H, Alakel N, Schaich M, Morgner A, Kramer M, Sockel K, von Bonin M, Stölzel F, Platzbecker U, Röllig C, Thiede C, Ehninger G, Bornhäuser M, Schetelig J.

Biol Blood Marrow Transplant. 2017 Sep;23(9):1491-1497. doi: 10.1016/j.bbmt.2017.05.014. Epub 2017 May 17.

PMID:
28527985
7.

Allogeneic hematopoietic cell transplantation for primary refractory acute lymphoblastic leukemia: A report from the Acute Leukemia Working Party of the EBMT.

Pavlů J, Labopin M, Zoellner AK, Sakellari I, Stelljes M, Finke J, Fanin R, Stuhler G, Afanasyev BV, Bloor AJ, Anagnostopoulos A, Mohty M, Giebel S, Nagler A.

Cancer. 2017 Jun 1;123(11):1965-1970. doi: 10.1002/cncr.30604. Epub 2017 Feb 17.

8.

Impact of Donor Activating KIR Genes on HSCT Outcome in C1-Ligand Negative Myeloid Disease Patients Transplanted with Unrelated Donors-A Retrospective Study.

Neuchel C, Fürst D, Niederwieser D, Bunjes D, Tsamadou C, Wulf G, Pfreundschuh M, Wagner E, Stuhler G, Einsele H, Schrezenmeier H, Mytilineos J.

PLoS One. 2017 Jan 20;12(1):e0169512. doi: 10.1371/journal.pone.0169512. eCollection 2017.

9.

Silencing of CDK2, but not CDK1, separates mitogenic from anti-apoptotic signaling, sensitizing p53 defective cells for synthetic lethality.

Nekova TS, Kneitz S, Einsele H, Bargou R, Stuhler G.

Cell Cycle. 2016 Dec;15(23):3203-3209. Epub 2016 Nov 10.

10.

Sequential Intensified Conditioning Regimen Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with Intermediate- or High-Risk Acute Myeloid Leukemia in Complete Remission: A Study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.

Malard F, Labopin M, Stuhler G, Bittenbring J, Ganser A, Tischer J, Michallet M, Kröger N, Schmid C, Huynh A, Hallek M, Savani BN, Mohty M, Nagler A.

Biol Blood Marrow Transplant. 2017 Feb;23(2):278-284. doi: 10.1016/j.bbmt.2016.11.002. Epub 2016 Nov 2.

11.

Matching for the MICA-129 polymorphism is beneficial in unrelated hematopoietic stem cell transplantation.

Fuerst D, Neuchel C, Niederwieser D, Bunjes D, Gramatzki M, Wagner E, Wulf G, Glass B, Pfreundschuh M, Einsele H, Arnold R, Stuhler G, Schaefer-Eckart K, Freitag S, Casper J, Kaufmann M, Wattad M, Hertenstein B, Klein S, Ringhoffer M, Mytilineos D, Tsamadou C, Mueller C, Schrezenmeier H, Mytilineos J.

Blood. 2016 Dec 29;128(26):3169-3176. doi: 10.1182/blood-2016-05-716357. Epub 2016 Nov 3.

12.

Allogeneic Hematopoietic Cell Transplantation in Multiple Myeloma: Focus on Longitudinal Assessment of Donor Chimerism, Extramedullary Disease, and High-Risk Cytogenetic Features.

Rasche L, Röllig C, Stuhler G, Danhof S, Mielke S, Grigoleit GU, Dissen L, Schemmel L, Middeke JM, Rücker V, Schreder M, Schetelig J, Bornhäuser M, Einsele H, Thiede C, Knop S.

Biol Blood Marrow Transplant. 2016 Nov;22(11):1988-1996. doi: 10.1016/j.bbmt.2016.08.024. Epub 2016 Aug 31.

13.

Clofarabine salvage therapy before allogeneic hematopoietic stem cell transplantation in patients with relapsed or refractory AML: results of the BRIDGE trial.

Middeke JM, Herbst R, Parmentier S, Bug G, Hänel M, Stuhler G, Schäfer-Eckart K, Rösler W, Klein S, Bethge W, Bitz U, Büttner B, Knoth H, Alakel N, Schaich M, Morgner A, Kramer M, Sockel K, von Bonin M, Stölzel F, Platzbecker U, Röllig C, Thiede C, Ehninger G, Bornhäuser M, Schetelig J.

Leukemia. 2016 Feb;30(2):261-7. doi: 10.1038/leu.2015.226. Epub 2015 Aug 18.

PMID:
26283567
14.

Control of relapsed or refractory acute myeloid leukemia by clofarabine in preparation for allogeneic stem cell transplant.

Loeffler C, Kapp M, Grigoleit GU, Mielke S, Loeffler J, Heuschmann PU, Malzahn U, Hupp E, Einsele H, Stuhler G.

Leuk Lymphoma. 2015;56(12):3365-9. doi: 10.3109/10428194.2015.1020059. Epub 2015 Sep 24.

PMID:
26014275
15.

Effect of ATG-F on B-cell reconstitution after hematopoietic stem cell transplantation.

Roll P, Muhammad K, Stuhler G, Grigoleit U, Einsele H, Tony HP.

Eur J Haematol. 2015 Dec;95(6):514-23. doi: 10.1111/ejh.12524. Epub 2015 Mar 13.

PMID:
25677646
16.

Myeloma cell sensitivity to bortezomib is associated with Dicer1 expression.

Stuhler G, Nekova TS.

Blood. 2014 Jul 24;124(4):657-8. doi: 10.1182/blood-2014-04-571257. No abstract available.

17.

Small molecule enhancers of rapamycin induce apoptosis in myeloma cells via GSK3A/B preferentially within a protective bone marrow microenvironment.

Nekova TS, Dotterweich J, Schütze N, Einsele H, Stuhler G.

Br J Haematol. 2014 Oct;167(2):272-4. doi: 10.1111/bjh.12967. Epub 2014 Jun 11. No abstract available.

PMID:
24916065
18.

Silencing of Dicer1 temporally separates pro- and anti-apoptotic signaling and confers susceptibility to chemotherapy in p53 mutated cells.

Nekova TS, Kneitz S, Einsele H, Stuhler G.

Cell Cycle. 2014;13(14):2192-8. doi: 10.4161/cc.29216. Epub 2014 May 20.

19.

KIR haplotype B donors but not KIR-ligand mismatch result in a reduced incidence of relapse after haploidentical transplantation using reduced intensity conditioning and CD3/CD19-depleted grafts.

Michaelis SU, Mezger M, Bornhäuser M, Trenschel R, Stuhler G, Federmann B, Oevermann L, Kanz L, Handgretinger R, Bethge WA.

Ann Hematol. 2014 Sep;93(9):1579-86. doi: 10.1007/s00277-014-2084-2. Epub 2014 Apr 26.

PMID:
24771045
20.

Haploidentical allogeneic hematopoietic cell transplantation in adults using CD3/CD19 depletion and reduced intensity conditioning: a phase II study.

Federmann B, Bornhauser M, Meisner C, Kordelas L, Beelen DW, Stuhler G, Stelljes M, Schwerdtfeger R, Christopeit M, Behre G, Faul C, Vogel W, Schumm M, Handgretinger R, Kanz L, Bethge WA.

Haematologica. 2012 Oct;97(10):1523-31. doi: 10.3324/haematol.2011.059378. Epub 2012 Apr 4.

21.

Prevention of major infectious complications by pre-emptive enterostomy in patients awaiting allogeneic stem cell transplantation.

Kapp M, Grigoleit GU, Dietz UA, Wiegering V, Stuhler G, Schlegel N, Einsele H, Mielke S, Germer CT, Strauss A.

Int J Colorectal Dis. 2012 Dec;27(12):1683-5. doi: 10.1007/s00384-012-1462-2. Epub 2012 Mar 22. No abstract available.

PMID:
22434557
22.

Allogeneic hematopoietic SCT in patients with AML following treosulfan/fludarabine conditioning.

Casper J, Holowiecki J, Trenschel R, Wandt H, Schaefer-Eckart K, Ruutu T, Volin L, Einsele H, Stuhler G, Uharek L, Blau I, Bornhaeuser M, Zander AR, Larsson K, Markiewicz M, Giebel S, Kruzel T, Mylius HA, Baumgart J, Pichlmeier U, Freund M, Beelen DW.

Bone Marrow Transplant. 2012 Sep;47(9):1171-7. doi: 10.1038/bmt.2011.242. Epub 2011 Dec 12.

PMID:
22158386
23.

Allogeneic stem cell transplantation in multiple myeloma relapsed after autograft: a multicenter retrospective study based on donor availability.

Patriarca F, Einsele H, Spina F, Bruno B, Isola M, Nozzoli C, Nozza A, Sperotto A, Morabito F, Stuhler G, Festuccia M, Bosi A, Fanin R, Corradini P.

Biol Blood Marrow Transplant. 2012 Apr;18(4):617-26. doi: 10.1016/j.bbmt.2011.07.026. Epub 2011 Aug 3.

24.

Reduced-toxicity conditioning with treosulfan and fludarabine in allogeneic hematopoietic stem cell transplantation for myelodysplastic syndromes: final results of an international prospective phase II trial.

Ruutu T, Volin L, Beelen DW, Trenschel R, Finke J, Schnitzler M, Holowiecki J, Giebel S, Markiewicz M, Uharek L, Blau IW, Kienast J, Stelljes M, Larsson K, Zander AR, Gramatzki M, Repp R, Einsele H, Stuhler G, Baumgart J, Mylius HA, Pichlmeier U, Freund M, Casper J.

Haematologica. 2011 Sep;96(9):1344-50. doi: 10.3324/haematol.2011.043810. Epub 2011 Jun 9.

25.

Endophthalmitis as primary clinical manifestation of fatal fusariosis in an allogeneic stem cell recipient.

Kapp M, Schargus M, Deuchert T, Springer J, Wendel F, Loeffler J, Grigoleit GU, Kurzai O, Heinz W, Einsele H, Stuhler G.

Transpl Infect Dis. 2011 Aug;13(4):374-9. doi: 10.1111/j.1399-3062.2011.00608.x. Epub 2011 Feb 16.

PMID:
21324055
26.

Phase behavior of an extended surfactant in water and a detailed characterization of the concentrated phases.

Klaus A, Tiddy GJ, Touraud D, Schramm A, Stühler G, Kunz W.

Langmuir. 2010 Nov 16;26(22):16871-83. doi: 10.1021/la103037q. Epub 2010 Oct 7.

PMID:
20929210
27.

Phase behavior of an extended surfactant in water and a detailed characterization of the dilute and semidilute phases.

Klaus A, Tiddy GJ, Touraud D, Schramm A, Stühler G, Drechsler M, Kunz W.

Langmuir. 2010 Apr 20;26(8):5435-43. doi: 10.1021/la903899w.

PMID:
20000427
28.

Clofarabine-based salvage chemotherapy for relapsed or refractory acute leukemia before allogeneic stem cell transplantation: results from a case series.

Grigoleit GU, Kapp M, Tan SM, Unzicker C, Einsele H, Mielke S, Topp MS, Stuhler G.

Leuk Lymphoma. 2009 Dec;50(12):2071-4. doi: 10.3109/10428190903350413. No abstract available.

PMID:
19886845
29.

Life-threatening infection caused by daptomycin-resistant Corynebacterium jeikeium in a neutropenic patient.

Schoen C, Unzicker C, Stuhler G, Elias J, Einsele H, Grigoleit GU, Abele-Horn M, Mielke S.

J Clin Microbiol. 2009 Jul;47(7):2328-31. doi: 10.1128/JCM.00457-09. Epub 2009 May 6.

30.

CD8+ T-cell responses to tumor-associated antigens correlate with superior relapse-free survival after allo-SCT.

Kapp M, Stevanović S, Fick K, Tan SM, Loeffler J, Opitz A, Tonn T, Stuhler G, Einsele H, Grigoleit GU.

Bone Marrow Transplant. 2009 Mar;43(5):399-410. doi: 10.1038/bmt.2008.426. Epub 2009 Jan 12.

PMID:
19139738
31.

Disseminated mucormycosis of an immunocompromised multiple myeloma patient: impact of biopsy of extramedullary tumours in refractory multiple myeloma.

Gattenlöhner S, Unzicker C, Wörner S, Stuhler G, Einsele H, Müller-Hermelink HK.

Ann Hematol. 2009 Apr;88(4):385-7. doi: 10.1007/s00277-008-0594-5. Epub 2008 Aug 29. No abstract available.

PMID:
18758780
32.

Five donors-one recipient: modeling a mosaic of granulocytes, natural killer and T cells from cord-blood and third-party donors.

Schöttker B, Feuchtinger T, Schumm M, Klinker E, Handgretinger R, Einsele H, Stuhler G.

Nat Clin Pract Oncol. 2008 May;5(5):291-5. doi: 10.1038/ncponc1105. Epub 2008 Mar 25.

PMID:
18364724
33.

Haploidentical allogeneic hematopoietic cell transplantation in adults using CD3/CD19 depletion and reduced intensity conditioning: an update.

Bethge WA, Faul C, Bornhäuser M, Stuhler G, Beelen DW, Lang P, Stelljes M, Vogel W, Hägele M, Handgretinger R, Kanz L.

Blood Cells Mol Dis. 2008 Jan-Feb;40(1):13-9. Epub 2007 Sep 14.

PMID:
17869547
34.

Reduced-toxicity conditioning with fludarabine and treosulfan prior to allogeneic stem cell transplantation in multiple myeloma.

Schmidt-Hieber M, Blau IW, Trenschel R, Andreesen R, Stuhler G, Einsele H, Kanz L, Keilholz U, Marinets O, Beelen DW, Fauser AA, Volin L, Ruutu T, Uharek L, Fietz T, Knauf W, Hopfenmüller W, Thiel E, Freund M, Casper J.

Bone Marrow Transplant. 2007 Apr;39(7):389-96. Epub 2007 Feb 19.

PMID:
17310135
35.

New avenues of hematopoietic stem cell transplantation.

Stuhler G, Einsele H.

J Stem Cells Regen Med. 2007 May 16;2(1):15. eCollection 2007. No abstract available.

PMID:
24692879
36.

Intravenously administered rituximab induces remission of EBV associated non Hodgkin lymphoma confined to the brain in a patient after allogeneic stem cell transplantation.

Stuhler G, Knop S, Topp MS, Kröber SM, Ernemann U, Herrlinger U, Einsele H, Kanz L, Hebart H.

Haematologica. 2006 Mar;91(3):ECR01. No abstract available.

37.

Mucormycoses in patients with hematologic malignancies: an emerging fungal infection.

Bethge WA, Schmalzing M, Stuhler G, Schumacher U, Kröber SM, Horger M, Einsele H, Kanz L, Hebart H.

Haematologica. 2005 Nov;90 Suppl:ECR22.

38.

Retraction: Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids.

Kugler A, Stuhler G, Walden P, Zöller G, Zobywalski A, Brossart P, Trefzer U, Ullrich S, Müller CA, Becker V, Gross AJ, Hemmerlein B, Kanz L, Müller GA, Ringert RH.

Nat Med. 2003 Sep;9(9):1221. No abstract available.

PMID:
12949529
39.

Apoptotic cells induce migration of phagocytes via caspase-3-mediated release of a lipid attraction signal.

Lauber K, Bohn E, Kröber SM, Xiao YJ, Blumenthal SG, Lindemann RK, Marini P, Wiedig C, Zobywalski A, Baksh S, Xu Y, Autenrieth IB, Schulze-Osthoff K, Belka C, Stuhler G, Wesselborg S.

Cell. 2003 Jun 13;113(6):717-30.

40.

Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells.

Brossart P, Wirths S, Stuhler G, Reichardt VL, Kanz L, Brugger W.

Blood. 2000 Nov 1;96(9):3102-8.

41.

Tumor necrosis factor alpha and CD40 ligand antagonize the inhibitory effects of interleukin 10 on T-cell stimulatory capacity of dendritic cells.

Brossart P, Zobywalski A, Grünebach F, Behnke L, Stuhler G, Reichardt VL, Kanz L, Brugger W.

Cancer Res. 2000 Aug 15;60(16):4485-92.

42.

Successful transplantation of highly selected CD34+ peripheral blood stem cells in a HLA-sensitized patient treated with immunoadsorption onto protein A.

Braun N, Faul C, Wernet D, Schnaidt M, Stuhler G, Kanz L, Risler T, Einsele H.

Transplantation. 2000 Apr 27;69(8):1742-4.

PMID:
10836395
43.

Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids.

Kugler A, Stuhler G, Walden P, Zöller G, Zobywalski A, Brossart P, Trefzer U, Ullrich S, Müller CA, Becker V, Gross AJ, Hemmerlein B, Kanz L, Müller GA, Ringert RH.

Nat Med. 2000 Mar;6(3):332-6. Retraction in: Kugler A, Stuhler G, Walden P, Zöller G, Zobywalski A, Brossart P, Trefzer U, Ullrich S, Müller CA, Becker V, Gross AJ, Hemmerlein B, Kanz L, Müller GA, Ringert RH. Nat Med. 2003 Sep;9(9):1221.

PMID:
10700237
44.

Human tumour and dendritic cell hybrids generated by electrofusion: potential for cancer vaccines.

Scott-Taylor TH, Pettengell R, Clarke I, Stuhler G, La Barthe MC, Walden P, Dalgleish AG.

Biochim Biophys Acta. 2000 Mar 17;1500(3):265-79.

45.

Induction of minor histocompatiblity antigen HA-1-specific cytotoxic T cells for the treatment of leukemia after allogeneic stem cell transplantation.

Brossart P, Spahlinger B, Grünebach F, Stuhler G, Reichardt VL, Kanz L, Brugger.

Blood. 1999 Dec 15;94(12):4374-6. No abstract available.

46.

Approaches to dendritic cell-based immunotherapy after peripheral blood stem cell transplantation.

Brugger W, Brossart P, Scheding S, Stuhler G, Heinrich K, Reichardt V, Grünebach F, Bühring HJ, Kanz L.

Ann N Y Acad Sci. 1999 Apr 30;872:363-71. Review.

PMID:
10372138
47.

Identification of HLA-A2-restricted T-cell epitopes derived from the MUC1 tumor antigen for broadly applicable vaccine therapies.

Brossart P, Heinrich KS, Stuhler G, Behnke L, Reichardt VL, Stevanovic S, Muhm A, Rammensee HG, Kanz L, Brugger W.

Blood. 1999 Jun 15;93(12):4309-17.

48.

Hybrid cell vaccination in cancer immunotherapy. Recruitment and activation of T cell help for induction of anti tumour cytotoxic T cells.

Stuhler G, Trefzer U, Walden P.

Adv Exp Med Biol. 1998;451:277-82. No abstract available.

PMID:
10026885
49.

Immune regulatory loops determine productive interactions within human T lymphocyte-dendritic cell clusters.

Stuhler G, Zobywalski A, Grünebach F, Brossart P, Reichardt VL, Barth H, Stevanovic S, Brugger W, Kanz L, Schlossman SF.

Proc Natl Acad Sci U S A. 1999 Feb 16;96(4):1532-5.

50.

Supplemental Content

Loading ...
Support Center